ImmunoPrecise to Lead Scientific Round-table Discussion
At hubXchange's European Antibody Therapeutics event, Debby Kruijsen will lead a round-table discussion entitled 'Implementing...
ImmunoPrecise’s Rapid Prime System Ensures a 65-Day Completion of Hybridoma Development Programs
As a leading provider of custom monoclonal and polyclonal antibody development with over 20 years of experience, ImmunoPrecise Antibodies is well-positioned to offer some of the fastest turnaround times in the industry.
The ImmunoPrecise Rapid Prime system reduces reduces the immunization stage of hybridoma development to just 18 days, shaving five to eight weeks off the industry standard. Combined with Clone EZ, ImmunoPrecise’s single-step cloning procedure, Rapid Prime can deliver complete hybridoma development programs in just 65 days.
Download this free white paper to find out more.
More About This Company
Second US Office for ImmunoPrecise Antibodies in Massachusetts
Immunoprecise Antibodies has announced that it has opened a new subsidiary office in Cambridge, Massachusetts,...
ImmunoPrecise Increases Private Placement to $0.80 per Unit
ImmunoPrecise Antibodies has increased its non-brokered private placement financing to 875,000 units of ImmunoPrecise at...